Feature | January 21, 2014

IMV Market Report Shows U.S. CT Procedure Volume Dropping

January 21, 2014 — Computed Tomography (CT) procedure rates have declined by an average annual 5.5 percent in the United States over the past two years, diverging from a previous decade-long growth trend, according to a survey conducted by IMV Medical Information Division. 
 
“This apparent decline in CT procedures over the past couple years may in part be due to the reimbursement policies of Medicare and third-party insurers, who have tightened their reimbursements for key CT studies,” said Lorna Young, senior director of market research at IMV.
 
Pressures on CT departments that are impacting procedure rates include reduced reimbursements, necessary prior authorization for imaging studies, upholding department accreditations and national and regional policy reforms. IMV’s survey revealed about two-thirds of CT providers agree “the impact of federal healthcare reform is so uncertain that our facility has slowed the rate of all capital equipment spending until we know what the outcome is.” 
 
Reportedly, independent imaging centers with budgets to balance are more sensitive than hospitals to revenue-diminishing reductions in Medicare payments and third-party reimbursements. 
 
For more information: www.imvinfo.com

Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now